<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977129</url>
  </required_header>
  <id_info>
    <org_study_id>2018CR001</org_study_id>
    <nct_id>NCT03977129</nct_id>
  </id_info>
  <brief_title>Quantitative Flow Ratio (QFR) Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease</brief_title>
  <acronym>FAVOR4-QVAS</acronym>
  <official_title>A Multicenter, Prospective, Randomized, Blind, Controlled Clinical Study to Compare the Efficacy of Quantitative Flow Ratio Guided and Coronary Angiography Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Med-X Research Institute, Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, randomized, blinded, controlled clinical study in&#xD;
      patients with planned primary valvular surgery and comorbid coronary artery lesions with&#xD;
      diameter stenosis of ≥ 50%, to compare the effectiveness of an Quantitative Flow Ratio&#xD;
      (QFR)-guided revascularization strategy and a coronary angiography (CAG)-guided&#xD;
      revascularization strategy in preventing the composite outcome (including all-cause death,&#xD;
      non-fatal myocardial infarction, non-fatal stroke, unplanned coronary revascularization, new&#xD;
      renal failure requiring dialysis) within 30 days after surgery. The study hypothesis is that&#xD;
      the QFR-guided strategy can reduce the incidence of the composite outcome within 30 days&#xD;
      after surgery, as compared with the CAG-guided strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is planned to enroll 792 subjects aged ≥18 years, with no gender restriction, who plan to&#xD;
      undergo elective open-heart valvular surgery due to primary valvular heart disease, with&#xD;
      comorbid coronary artery lesions defined as diameter stenosis of ≥ 50% (visual estimation)&#xD;
      that are diagnosed by CAG before the surgery.&#xD;
&#xD;
      QFR group: Calculate the QFR values of all target coronary arteries (anterior descending&#xD;
      branch, circumflex branch, main right coronary artery or its primary branches with ≥ 1.5 mm&#xD;
      in diameter, such as diagonal branch, intermediate branch, obtuse marginal branch, posterior&#xD;
      descending branch and posterior branch of left ventricle) with lesions with diameter stenosis&#xD;
      of ≥ 50% (visual estimation) suited for CABG revascularization. If QFR ≤ 0.80, then&#xD;
      simultaneous CABG revascularization of target blood vessels will be carried out. If QFR &gt;&#xD;
      0.80, then no CABG revascularization of target blood vessels will be carried out.&#xD;
&#xD;
      CAG group (control group): All target coronary arteries (anterior descending branch,&#xD;
      circumflex branch, main right coronary artery or its primary branches with ≥ 1.5 mm in&#xD;
      diameter, such as diagonal branch, intermediate branch, obtuse marginal branch, posterior&#xD;
      descending branch and posterior branch of left ventricle) with lesions with diameter stenosis&#xD;
      of ≥ 50% (visual estimation) suited for CABG revascularization will undergo simultaneous CABG&#xD;
      revascularization.&#xD;
&#xD;
      Intervention duration: The assessments will be performed after randomization and before the&#xD;
      surgery to guide the surgery.&#xD;
&#xD;
      No planned interim analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of composite outcome including all-cause death, non-fatal myocardial infarction, non-fatal stroke, unplanned coronary revascularization and new renal failure requiring dialysis</measure>
    <time_frame>within 30 days after surgery</time_frame>
    <description>Compare the incidence of composite outcome between two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time from randomization to first occurrence of any of composite outcome</measure>
    <time_frame>within 1 year after surgery</time_frame>
    <description>The time from randomization to first occurrence of any of composite outcome including all-cause death, non-fatal myocardial infarction, non-fatal stroke, unplanned coronary revascularization, hospitalization or urgent visits for unstable angina pectoris and hospitalization or urgent visits for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of graft failure (stenosis ≥ 50% or occlusion occurred in grafts or distal anastomosis)</measure>
    <time_frame>at 1 year after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time from randomization to first occurrence of any of composite outcome</measure>
    <time_frame>within 3 years after surgery</time_frame>
    <description>The time from randomization to first occurrence of any of composite outcome including all-cause death, non-fatal myocardial infarction, non-fatal stroke, unplanned coronary revascularization, hospitalization or urgent visits for unstable angina pectoris and hospitalization or urgent visits for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of graft failure (stenosis ≥ 50% or occlusion occurred in grafts or distal anastomosis)</measure>
    <time_frame>at 3 years after surgery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The number of grafts per person (counted as distal anastomosis)</measure>
    <time_frame>at Day 0</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The total circulatory time during the surgery (minutes)</measure>
    <time_frame>at Day 0</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The total cross-clamp time during the surgery (minutes)</measure>
    <time_frame>at Day 0</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The total units of erythrocyte transfusion during and after the surgery till discharge</measure>
    <time_frame>from Day 0 to discharge day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number of days from surgery day to discharge day</measure>
    <time_frame>from Day 0 to discharge day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the Canadian Cardiac Society (CCS) anginal status score (0-4)</measure>
    <time_frame>at 1 year after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the CCS anginal status score (0-4)</measure>
    <time_frame>at 3 years after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the New York Heart Association (NYHA) score (1-4)</measure>
    <time_frame>at 1 year after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the NYHA score (1-4)</measure>
    <time_frame>at 3 years after surgery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">792</enrollment>
  <condition>Primary Valvular Heart Disease With Comorbid Coronary Artery Disease</condition>
  <condition>Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>QFR group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CAG group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QFR-guided strategy</intervention_name>
    <description>In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR &gt; 0.80, then no CABG revascularization of target blood vessels will be carried out.</description>
    <arm_group_label>QFR group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CAG-guided strategy</intervention_name>
    <description>In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.</description>
    <arm_group_label>CAG group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily participate in the trial and provide the informed consent form;&#xD;
&#xD;
          -  Male or female patients aged ≥ 18 years;&#xD;
&#xD;
          -  Planned to undergo elective on-pump valve surgery due to primary mitral and/or aortic&#xD;
             valvular heart disease (such as rheumatic, degenerative, infective, congenital&#xD;
             valvular heart disease, etc.);&#xD;
&#xD;
          -  At least one target coronary arteries (anterior descending branch, circumflex branch,&#xD;
             main right coronary artery or its primary branches with ≥ 1.5 mm in diameter, such as&#xD;
             diagonal branch, intermediate branch, obtuse marginal branch, posterior descending&#xD;
             branch and posterior branch of left ventricle) with preoperative diameter stenosis of&#xD;
             ≥ 50% by coronary angiography (visual estimation, subject to written coronary&#xD;
             angiography report) and suited for CABG revascularization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of heart surgery;&#xD;
&#xD;
          -  Planned second-stage PCI or CABG revascularization;&#xD;
&#xD;
          -  Secondary valvular heart disease (ischemia, cardiomyopathy);&#xD;
&#xD;
          -  Planned valve intervention surgery through the catheter;&#xD;
&#xD;
          -  Subjects that were evaluated to have cardiogenic shock or other critical conditions&#xD;
             that were not appropriate for the trial by study physician;&#xD;
&#xD;
          -  QFR calculations cannot be carried out from preoperative coronary angiography data&#xD;
             (such as poor projection position, inability to detect vascular boundaries, poor&#xD;
             contrast agent filling, excessive overlap or severely distorted of vessel lesion&#xD;
             sections, lesion involved in myocardial bridge, or lesion site within 3 mm from the&#xD;
             ostium of the main coronary artery);&#xD;
&#xD;
          -  The target coronary arteries were evaluated to be not suitable for CABG by study&#xD;
             physician;&#xD;
&#xD;
          -  Life expectancy &lt; 3 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Zhao, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shengxian Tu, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med-X Research Institute, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yunpeng Zhu, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunpeng Zhu, MD.</last_name>
    <phone>+8613816819346</phone>
    <email>Zyp12220@rjh.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai Central China Cardiovascular Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junlong Hu, MD.</last_name>
      <email>dr_hu@henu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Zhaoyun Cheng, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junlong Hu, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second XiangYa Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Zhao, MD.</last_name>
      <email>drzhaoyuan@163.com</email>
    </contact>
    <investigator>
      <last_name>Xinmin Zhou, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuan Zhao, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kang Zhou, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunpeng Zhu, MD.</last_name>
      <phone>+8613816819346</phone>
      <email>Zyp12220@rjh.com.cn</email>
    </contact>
    <investigator>
      <last_name>Qiang Zhao, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yunpeng Zhu, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiaxi Zhu, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yiwei Xu, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Xue, MD.</last_name>
      <email>xq9911310@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhiyun Xu, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lin Han, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qing Xue, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Busheng Zhang, MD.</last_name>
      <email>albmu@sina.cn</email>
    </contact>
    <investigator>
      <last_name>Dan Zhu, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Busheng Zhang, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Qiang Zhao,MD</investigator_full_name>
    <investigator_title>Professor and Director, Department of Cardiovascular Surgery, Vice President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

